WELL Beat on Revenue and Guidance-Then Dropped. Is Q2 a Buying Window at $4?

WELL's post-earnings drop looks more like lingering caution than a clean fundamental verdict

WELL delivered CAD 400 million in Q2 revenue, up 12% year over year, and CAD 395.6 million on a normalized basis, up 14%. It also raised its full-year outlook. Even so, the shares fell 1.96% to $4.01 in after-hours trading. The reaction suggests investors are still weighing older doubts more heavily than the freshest operating evidence.

The price action stabilized quickly

The selloff did not hold. WELL rebounded to $4.15 on the last trading day, and the technical read moved from Sell to Hold/Accumulate. That does not guarantee a rerating, but it does suggest the immediate panic faded.

At about $4.01 to $4.15, WELL is not obviously cheap. It is, at most, optionally cheap: the setup improves only if the next few reports turn raised guidance into credibility.

Canadian Patient Services is doing most of the heavy lifting

The clearest change in the story is regional. Canada is not just growing; it is becoming the larger part of the business.

Canadian Patient Services is compounding on both revenue and profit

In Q2, Canadian Patient Services revenue increased 32% to $151.6 million, while adjusted EBITDA in that business increased 22% to $22.3 million. That points to a core segment gaining scale and profitability at the same time, not simply absorbing acquisition noise.

The same pattern was already visible in Q1

That is not a one-quarter anomaly. In Q1, revenue rose 25% year over year, patient visits increased 17%, and Canadian patient services visits grew 33%. Canadian Patient Services revenue was up 30% to $130.3 million, and adjusted EBITDA in the business increased 28% to $17.0 million. Management also reported organic growth of 8% for the Canadian Patient Services business and 13% organic growth in Canada.

The clinic network and software platform are broadening together

With the OID Group and UnionMD closings, WELL's Canadian Clinics network expanded to 275 clinics, and WELL Canada's annualized Adjusted EBITDA run-rate to over $100 million, three calendar quarters ahead of schedule. At the same time, WELLSTAR revenue climbed 37% to CAD 23 million, helped by an Ontario e-referral win and broader adoption.

Taken together, these figures support a simpler conclusion than the market reaction suggested: the Canadian clinic network is scaling, and the technology platform is growing alongside it.

The real debate is how to read adjusted EBITDA

WELL's Q2 profitability headline gave bulls and bears different places to stand.

Reported EBITDA fell, but the prior-year comparison was favorably distorted

WELL's reported adjusted EBITDA fell 3%, but the company said that reflected Circle Medical Deferrals making Q2 2025 higher by $9.7 million. The cleaner comparison is CAD 43.3 million normalized, with the normalized figure up 8% from a year earlier. Bears can still argue the reported line matters because it is what the market sees first. Bulls can argue the distorted comparison understates the underlying trend.

Raised guidance makes the story harder to dismiss

This is not a story in which growth is stalling and management is only talking about long-term upside. WELL both raised its full-year outlook and showed better normalized profit progression. The skeptical read is still reasonable: one strong quarter, even with normalization, is not the same as fully cleared execution. But the evidence is no longer consistent with a simple broken-growth thesis.

Analyst splits and valuation leave room for another repricing

The market is not speaking with one voice here. The rating mix sits at four Buy ratings and three Sell ratings, with the latest call labeled WATCH. That kind of split often means the stock is still sensitive to the next proof point rather than locked into a settled view.

At roughly $4, WELL does not look deeply undervalued on its own. But if management can deliver a few more quarters that back up the raised targets, the stock may not need unanimous optimism to move higher. The key watch items are straightforward:

• Keep watching normalized profit, not just the reported EBITDA headline.
• Watch whether Canada keeps driving growth in revenue, visits, and profitability.
• Watch whether the company preserves the technical improvement from Sell to Hold/Accumulate as sentiment settles.

For now, the cleaner read is that WELL's Q2 did not justify a lasting negative reaction on its own. Whether the shares become a true buying window will depend on whether the next reports turn a good quarter into a durable trend.